🧬 Introduction

Camzyos, generic mavacamten, is the first approved cardiac myosin inhibitor, used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). It works by reducing excessive contraction of heart muscle, improving symptoms and activity tolerance

💊 Composition / Salt

• Active Molecule: Mavacamten

• Drug Class: Cardiac myosin inhibitor; selectively modulates myosin heads to alleviate hypercontractility

• Formulation: Oral capsules

• Approved For: Adults with NYHA Class II–III obstructive HCM

📝 Dosage & Administration

• Usual Dose: Once-daily oral dose (strength personalized based on individual patient assessment; typical dosing starts at 5 mg/day and is titrated by echocardiogram)

• Monitoring:

  • Requires specialized titration based on echocardiographic findings

  • Available only through the Camzyos REMS Program, which mandates certified providers, pharmacies, and patients

⚠️ Side Effects

    Common:

• Dizziness, syncope

• Headache, fatigue

• Shortness of breath
  

     Serious Risk:

• Heart failure due to systolic dysfunction

🚨 Warnings & Precautions

• Heart failure risk: performance must be monitored closely; discontinue if LVEF becomes dangerously low

• REMS program: Only accessible via certified clinicians, pharmacies, and patients, with regular echocardiographic monitoring

✅ Conclusion

Camzyos (mavacamten) represents a novel, targeted treatment for symptomatic obstructive HCM, with the unique ability to directly modulate cardiac myosin function. Its use requires specialized monitoring and enrollment in a controlled REMS program due to the serious risk of heart failure. Ongoing monitoring ensures safety and optimal therapeutic benefit.